Recent developments in gene transfer: risk and ethicsBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7482.79 (Published 06 January 2005) Cite this as: BMJ 2005;330:79
- Jonathan Kimmelman, research associate (email@example.com)1
- 1 Clinical Trials Research Group, Biomedical Ethics Unit, Faculty of Medicine, McGill University, 3647 Peel Street, Montreal, QC, Canada H3A 1X1
- Accepted 9 November 2004
Since the early 1990s, investigators have toiled to establish the transfer of genes to human somatic cells as a valid therapy (fig 1). The potential of gene transfer was highlighted by three trials, involving participants with haemophilia B and two types of severe combined immunodeficiency—X linked and adenosine deaminase deficient.1–3 Yet even the most successful trials of gene transfer have engendered questions about its prospects. In the haemophilia B trial the detection of vector—the agent which carries genes to cells (fig 2)—in participants' semen raised concerns about modifications of the germline.4 The results of the X linked severe combined immunodeficiency trial were offset by unexpected, vector induced leukaemia in two participants.5
Several hazards associated with gene transfer have been verified by clinical experience and others are predicted on theoretical grounds. It therefore may be worth considering whether risks shown in studies of human gene transfer present any unusual ethical and social challenges and, if so, what should be done to tackle them. In this article I review several matters relating to human gene transfer—safety features that distinguish traditional drugs from agents used to transfer genes, ethical issues raised by uncertainties about risk and toxicological properties, and studies on safety.
Sources and selection criteria
I searched for relevant articles in Medline through PubMed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial